FilingSEC EDGAR8-K
Vistagen Therapeutics Announces Exploratory Clinical Data for Fasedienol Nasal Spray
· SEC accepted
StagePhase 3
Filing content
The company announced positive exploratory efficacy signals for fasedienol in patients with very severe social anxiety disorder.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…